Indacaterol: A Novel Long‐Acting β2‐Agonist

Pharmacotherapy - Tập 32 Số 5 - Trang 456-474 - 2012
Shaunta’ M. Ray1,2, J. Curtis McMillen3, Sarah T. Eudaley4,5, Robert S. Helmer1,3, Andrea S. Franks1,2
1Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, Knoxville, Tennessee
2Department of Family Medicine, University of Tennessee Graduate School of Medicine, Knoxville, Tennessee
3Department of Pharmacy, University of Tennessee Medical Center, Knoxville, Tennessee
4Department of Family Medicine, University of South Alabama, Mobile, Alabama
5Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Mobile, Alabama

Tóm tắt

Bronchodilator drugs are the foundation for the treatment of chronic obstructive pulmonary disease. The principal inhaled bronchodilator treatments used are β2‐agonists and anticholinergics, either alone or in combination. Currently available β2‐agonists are of either short duration and used multiple times/day, or of long duration, which requires twice‐daily administration. Indacaterol is considered an ultra–long‐acting β2‐agonist and was recently approved for use in the United States. Its duration of action is approximately 24 hours, allowing for once‐daily administration. Cough was the most commonly reported adverse effect with use of indacaterol. Cough usually occurred within 15 seconds of inhalation of the drug, lasted around 6 seconds, was not associated with bronchospasm, and did not cause discontinuation of the drug. Otherwise, the drug's safety profile was similar to that of other bronchodilators. Based on similar improvement in spirometric measurements compared with other bronchodilator drugs and the convenience of its once‐daily dosing, indacaterol may be beneficial in the management of mild‐to‐moderate chronic obstructive pulmonary disease, either alone or in combination with anticholinergic drugs administered once/day.

Từ khóa


Tài liệu tham khảo

2009, Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease

National Heart Lung and Blood Institute.National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma; 2007 Aug 28. Available fromhttp://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed September 2011.

10.1183/09031936.00060006

10.2165/00003495-200767040-00002

10.1038/bjp.2008.284

Novartis receives FDA approval for Arcapta™Neohaler™ a novel once‐daily bronchodilator for chronic obstructive pulmonary disease. Novartis Pharmaceuticals Corporation. Media Release July 2011. Available fromhttp://www.novartis.com/newsroom/media-releases/en/2011/1528013.shtml. Accessed September 2011.

10.1124/jpet.107.129296

10.1183/09031936.00032806

10.1124/jpet.105.098251

10.1016/j.rmed.2008.02.001

10.2174/1874306400903010027

10.1016/j.pupt.2006.09.001

10.1185/030079907X242863

10.1080/02770900802348321

10.1111/j.1398-9995.2007.01555.x

10.1185/03007990802675096

10.1016/j.pupt.2010.01.003

10.1016/S1081-1206(10)60840-X

10.1185/03007990903143143

10.1016/j.rmed.2010.06.011

10.1186/1471-2466-10-11

10.1016/j.pupt.2009.05.001

Balint B, 2010, Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol‐fluticasone, Int J Chron Obstruct Pulmon Dis, 5, 311

10.1186/1465-9921-11-135

10.1016/j.pupt.2010.06.005

10.1164/rccm.200910-1500OC

10.1183/09031936.00045810

10.1136/thx.2009.125435

FDA News Release. FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease. Unpublished results presented in NDA 022‐383 March 2011. Available athttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm261649.htm. Accessed March 2012.

Novartis. A 12-Week Treatment Multi-Center Randomized Double-Blind Placebo-Controlled Parallel-Group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients with Chronic Obstructive Pulmonary Disease. Unpublished results presented in NDA 022-383 March 2011. Available fromhttp://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM245637.pdf. Accessed October 2011.

10.1159/000327206

10.1016/j.rmed.2007.11.004

Duvauchelle T, 2005, Eur Respir J, 26

10.1016/j.rmed.2007.06.002

10.1016/S1081-1206(10)60386-9

10.5414/CPP49153

10.1016/j.rmed.2010.08.010

2010, CG101 chronic obstructive pulmonary disease (update): full guideline

10.1136/thorax.58.5.399

10.1378/chest.122.1.47

10.1016/j.rmed.2008.07.020

Thông tin
Thông tin xuất bản

Pharmacotherapy

Tập 32 Số 5

456-474

Thông tin tác giả